The PRDX2 gene is transcriptionally silenced and de novo methylated in Hodgkin and Reed-Sternberg cells of classical Hodgkin lymphoma.

In a recent issue of Blood, Agrawal-Singh et al reported the identification of PRDX2 (peroxiredoxin 2) as a novel tumor suppressor gene in acute myeloid leukemia (AML). The authors observed recurrent histone H3 deacetylation and DNA hypermethylation at the PRDX2 promoter region in primary leukemia samples. Epigenetic alterations correlated with low expression of PRDX2 protein and were associated with poor prognosis in AML patients. Moreover, the authors demonstrated that this gene acts as a growth inhibitor